Fiorenza D De Rose

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1434394/publications.pdf

Version: 2024-02-01

78 papers

1,714 citations

236912 25 h-index 330122 37 g-index

78 all docs 78 docs citations

78 times ranked 2630 citing authors

#	Article	IF	Citations
1	Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach. BMC Cancer, 2014, 14, 619.	2.6	86
2	Stereotactic body radiation therapy for lung metastases from soft tissue sarcoma. European Journal of Cancer, 2015, 51, 668-674.	2.8	83
3	Stereotactic body radiotherapy (sbrt) in lung oligometastatic patients: role of local treatments. Radiation Oncology, 2014, 9, 91.	2.7	81
4	Can Stereotactic Body Radiation Therapy Be a Viable and Efficient Therapeutic Option for Unresectable Locally Advanced Pancreatic Adenocarcinoma? Results of a Phase 2 Study. Technology in Cancer Research and Treatment, 2017, 16, 295-301.	1.9	80
5	Hypo-fractionated stereotactic radiotherapy alone using volumetric modulated arc therapy for patients with single, large brain metastases unsuitable for surgical resection. Radiation Oncology, 2016, 11, 76.	2.7	59
6	Performance of a Knowledge-Based Model for Optimization of Volumetric Modulated Arc Therapy Plans for Single and Bilateral Breast Irradiation. PLoS ONE, 2015, 10, e0145137.	2.5	55
7	Stereotactic body radiation therapy: A promising chance for oligometastatic breast cancer. Breast, 2016, 26, 11-17.	2.2	51
8	Dosimetric trade-offs in breast treatment with VMAT technique. British Journal of Radiology, 2017, 90, 20160701.	2.2	51
9	Automatic delineation for replanning in nasopharynx radiotherapy: What is the agreement among experts to be considered as benchmark?. Acta Oncológica, 2013, 52, 1417-1422.	1.8	49
10	Predictive factors for survival of oligometastatic colorectal cancer treated with Stereotactic body radiation therapy. Radiotherapy and Oncology, 2019, 133, 220-226.	0.6	49
11	Clinical Outcome of Stereotactic Ablative Body Radiotherapy for Lung Metastatic Lesions in Non-small Cell Lung Cancer Oligometastatic Patients. Clinical Oncology, 2016, 28, 13-20.	1.4	47
12	Phase II trial of hypofractionated VMAT-based treatment for early stage breast cancer: 2-year toxicity and clinical results. Radiation Oncology, 2016, 11, 120.	2.7	38
13	Stereotactic Body Radiation Therapy in Oligometastatic Ovarian Cancer: A Promising Therapeutic Approach. International Journal of Gynecological Cancer, 2018, 28, 1507-1513.	2,5	35
14	Minimally Invasive Stereotactical Radio-ablation of Adrenal Metastases as an Alternative to Surgery. Cancer Research and Treatment, 2017, 49, 20-28.	3.0	34
15	Comorbidity, postoperative morbidity and survival in patients undergoing radical surgery for malignant pleural mesothelioma. European Journal of Cardio-thoracic Surgery, 2016, 50, 1077-1082.	1.4	33
16	High-quality Linac-based Stereotactic Body Radiation Therapy with Flattening Filter Free Beams and Volumetric Modulated Arc Therapy for Low–Intermediate Risk Prostate Cancer. A Mono-institutional Experience with 90 Patients. Clinical Oncology, 2016, 28, e173-e178.	1.4	33
17	Low-dose fractionated radiotherapy and concomitant chemotherapy in glioblastoma multiforme with poor prognosis: a feasibility study. Neuro-Oncology, 2012, 14, 79-86.	1.2	32
18	Hypofractionated stereotactic radiation therapy in skull base meningiomas. Journal of Neuro-Oncology, 2015, 124, 283-289.	2.9	31

#	Article	IF	CITATIONS
19	Radiotherapy and immunotherapy: Can this combination change the prognosis of patients with melanoma brain metastases?. Cancer Treatment Reviews, 2016, 50, 1-8.	7.7	30
20	Predictive Factors for Response and Survival in a Cohort of Oligometastatic Patients Treated With Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2019, 104, 111-121.	0.8	30
21	Can Elderly Patients With Newly Diagnosed Glioblastoma be Enrolled in Radiochemotherapy Trials?. American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 23-27.	1.3	29
22	Critical Appraisal of the Risk of Secondary Cancer Induction From Breast Radiation Therapy With Volumetric Modulated Arc Therapy Relative to 3D Conformal Therapy. International Journal of Radiation Oncology Biology Physics, 2018, 100, 785-793.	0.8	29
23	Omission of postoperative radiation after breast conserving surgery: A progressive paradigm shift towards precision medicine. Clinical and Translational Radiation Oncology, 2020, 21, 112-119.	1.7	27
24	The use of radiation therapy for oligoprogressive/oligopersistent oncogene-driven non small cell lung cancer: State of the art. Critical Reviews in Oncology/Hematology, 2020, 148, 102894.	4.4	27
25	Role of stereotactic body radiation therapy for lung metastases from radio-resistant primary tumours. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1293-1299.	2.5	26
26	Critical appraisal of the role of volumetric modulated arc therapy in the radiation therapy management of breast cancer. Radiation Oncology, 2017, 12, 200.	2.7	26
27	Critical Appraisal of the Treatment Planning Performance of Volumetric Modulated Arc Therapy by Means of a Dual Layer Stacked Multileaf Collimator for Head and Neck, Breast, and Prostate. Technology in Cancer Research and Treatment, 2018, 17, 153303381880388.	1.9	26
28	Postmastectomy radiation therapy using VMAT technique for breast cancer patients with expander reconstruction. Medical Oncology, 2019, 36, 48.	2.5	25
29	Organs at risk in lung SBRT. Physica Medica, 2017, 44, 131-138.	0.7	24
30	Present clinical practice of breast cancer radiotherapy in Italy: a nationwide survey by the Italian Society of Radiotherapy and Clinical Oncology (AIRO) Breast Group. Radiologia Medica, 2020, 125, 674-682.	7.7	24
31	The Potential Role of Intensity-modulated Proton Therapy in the Regional Nodal Irradiation of Breast Cancer: A Treatment Planning Study. Clinical Oncology, 2020, 32, 26-34.	1.4	22
32	Multimodality therapy approaches, local and systemic treatment, compared with chemotherapy alone in recurrent glioblastoma. BMC Cancer, 2015, 15, 486.	2.6	21
33	Variability in axillary lymph node delineation for breast cancer radiotherapy in presence of guidelines on a multi-institutional platform. Acta Oncol \tilde{A}^3 gica, 2017, 56, 1081-1088.	1.8	21
34	Low-dose radiotherapy as a chemo-potentiator of a chemotherapy regimen with pemetrexed for recurrent non-small-cell lung cancer: A prospective phase II study. Radiotherapy and Oncology, 2012, 105, 161-166.	0.6	19
35	Radiation therapy of anal canal cancer: from conformal therapy to volumetric modulated arc therapy. BMC Cancer, 2014, 14, 833.	2.6	19
36	SBRT for lung oligometastases: Who is the perfect candidate?. Reports of Practical Oncology and Radiotherapy, 2015, 20, 446-453.	0.6	17

#	Article	IF	Citations
37	Applying Lean-Six-Sigma Methodology in radiotherapy: Lessons learned by the breast daily repositioning case. Radiotherapy and Oncology, 2018, 127, 326-331.	0.6	17
38	Role of Stereotactic Body Radiation Therapy with Volumetric-Modulated Arcs and High-Intensity Photon Beams for the Treatment of Abdomino-Pelvic Lymph-Node Metastases. Cancer Investigation, 2016, 34, 348-354.	1.3	16
39	The role of stereotactic body radiation therapy (SBRT) in the treatment of oligometastatic disease in the elderly. British Journal of Radiology, 2015, 88, 20150111.	2.2	15
40	Surgery Followed by Hypofractionated Radiosurgery on the Tumor Bed in Oligometastatic Patients With Large Brain Metastases. Results of a Phase 2 Study. International Journal of Radiation Oncology Biology Physics, 2019, 105, 1095-1105.	0.8	15
41	The role of SBRT in oligometastatic patients with liver metastases from breast cancer. Reports of Practical Oncology and Radiotherapy, 2017, 22, 163-169.	0.6	14
42	Role of extra cranial stereotactic body radiation therapy in the management of Stage IV melanoma. British Journal of Radiology, 2017, 90, 20170257.	2.2	14
43	Hypofractionation with simultaneous boost in breast cancer patients receiving adjuvant chemotherapy: A prospective evaluation of a case series and review of the literature. Breast, 2018, 42, 31-37.	2.2	14
44	Predictive factors for survival outcomes of oligometastatic prostate cancer patients treated with metastases-directed therapy: a recursive partitioning-based analysis. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2469-2479.	2.5	14
45	Intensity modulated proton therapy compared to volumetric modulated arc therapy in the irradiation of young female patients with hodgkin's lymphoma. Assessment of risk of toxicity and secondary cancer induction. Radiation Oncology, 2020, 15, 12.	2.7	14
46	Rethinking breast cancer follow-up based on individual risk and recurrence management. Cancer Treatment Reviews, 2022, 109, 102434.	7.7	14
47	Stereotactic/hypofractionated body radiation therapy as an effective treatment for lymph node metastases from colorectal cancer: an institutional retrospective analysis. British Journal of Radiology, 2017, 90, 20170422.	2.2	13
48	Volumetric modulated arc therapy for thoracic node metastases: a safe and effective treatment for a neglected disease. Oncotarget, 2016, 7, 53321-53329.	1.8	13
49	Use of PTW-microDiamond for relative dosimetry of unflattened photon beams. Physica Medica, 2017, 38, 45-53.	0.7	12
50	AÂradiomic approach to predicting nodal relapse and disease-specific survival in patients treated with stereotactic body radiation therapy for early-stage non-small cell lung cancer Strahlentherapie Und Onkologie, 2020, 196, 922-931.	2.0	12
51	Combined Modality Therapy for Thoracic and head and Neck Cancers: A Review of Updated Literature Based on a Consensus Meeting. Tumori, 2016, 102, 459-471.	1.1	11
52	Hypofractionated Whole Breast Irradiation and Simultaneous Integrated Boost in Large-breasted Patients: Long-term Toxicity and Cosmesis. Clinical Breast Cancer, 2020, 20, 527-533.	2.4	11
53	Survival outcome of tyrosine kinase inhibitors beyond progression in association to radiotherapy in oligoprogressive EGFR-mutant non-small-cell lung cancer. Future Oncology, 2019, 15, 3775-3782.	2.4	10
54	A national multicenter study on 1072 DCIS patients treated with breast-conserving surgery and whole breast radiotherapy (COBCG-01 study). Radiotherapy and Oncology, 2019, 131, 208-214.	0.6	9

#	Article	IF	CITATIONS
55	Local Treatment of the Axilla in Early Breast Cancer: So Many Questions, Still Few Answers. Clinical Oncology, 2020, 32, e37-e38.	1.4	9
56	Adjuvant volumetric modulated arc therapy compared to 3D conformal radiation therapy for newly diagnosed soft tissue sarcoma of the extremities: outcome and toxicity evaluation. British Journal of Radiology, 2019, 92, 20190252.	2.2	8
57	Prognostic factors and outcome of HER2+ breast cancer with CNS metastases. Future Oncology, 2020, 16, 269-279.	2.4	8
58	Radical hypo-fractionated radiotherapy with volumetric modulated arc therapy in lung cancer. Strahlentherapie Und Onkologie, 2017, 193, 385-391.	2.0	7
59	Evaluation of target dose inhomogeneity in breast cancer treatment due to tissue elemental differences. Radiation Oncology, 2018, 13, 92.	2.7	7
60	Breast reconstruction and radiation therapy: An Italian expert Delphi consensus statements and critical review. Cancer Treatment Reviews, 2021, 99, 102236.	7.7	7
61	Linac-based stereotactic body radiation therapy vs moderate hypofractionated radiotherapy in prostate cancer: propensity-score based comparison of outcome and toxicity. British Journal of Radiology, 2019, 92, 20190021.	2.2	6
62	Stereotactic Body Radiation Therapy for Intermediate-risk Prostate Cancer With VMAT and Real-time Electromagnetic Tracking. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 628-635.	1.3	6
63	Geometric contour variation in clinical target volume of axillary lymph nodes in breast cancer radiotherapy: an AIRO multi-institutional study. British Journal of Radiology, 2021, 94, 20201177.	2.2	6
64	Outcome Evaluation of HER2 Breast Cancer Patients with Limited Brain Metastasis. Anticancer Research, 2017, 37, 7057-7062.	1.1	6
65	Outcome appraisal of patients with limited brain metastases (BMs) from non small cell lung cancer (NSCLC) treated with different local therapeutic strategies: a single institute evaluation. British Journal of Radiology, 2017, 90, 20170022.	2.2	5
66	Recursive partitioning model-based analysis for survival of colorectal cancer patients with lung and liver oligometastases treated with stereotactic body radiation therapy. Journal of Cancer Research and Clinical Oncology, 2020, 146, 1227-1234.	2.5	5
67	Hypofractionated volumetric modulated arc therapy in ductal carcinoma <i>in situ</i> : toxicity and cosmetic outcome from a prospective series. British Journal of Radiology, 2018, 91, 20170634.	2.2	4
68	Can thoracic nodes oligometastases be safely treated with image guided hypofractionated radiation therapy?. British Journal of Radiology, 2019, 92, 20181026.	2.2	4
69	Volumetric Modulated Arc Therapy After Lung Sparing Surgery for Malignant Pleural Mesothelioma: A Single Institution Experience. Clinical Lung Cancer, 2020, 21, 86-93.	2.6	4
70	Biological Characteristics and Long-term Outcomes in Node-negative Breast Cancer. Clinical Breast Cancer, 2020, 20, e481-e489.	2.4	4
71	Outcome and toxicity profiles in the treatment of locally advanced lung cancer with volumetric modulated arc therapy. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1937-1945.	2.5	3
72	Comparing hypofractionated and conventionally fractionated whole breast irradiation for patients with ductal carcinoma in situ after breast conservation: a propensity score-matched analysis from a national multicenter cohort (COBCG-02 study). Journal of Cancer Research and Clinical Oncology, 2021, 147, 2069-2077.	2.5	3

#	Article	IF	CITATIONS
73	Lymph nodal radiotherapy in breast cancer: what are the unresolved issues?. Expert Review of Anticancer Therapy, 2021, 21, 827-840.	2.4	3
74	The dosimetric impact of axillary nodes contouring variability in breast cancer radiotherapy: An AIRO multi-institutional study. Radiotherapy and Oncology, 2022, 168, 113-120.	0.6	2
75	P2.05-008 Can Stereotactic Body Radiation Therapy (SBRT) Be an Effective Treatment for Lung Metastases From "Radioresistant―Histologies?. Journal of Thoracic Oncology, 2017, 12, S1035.	1.1	O
76	EP-1605 Adjuvant RT for soft tissue sarcomas: volumetric modulated arc therapy vs 3D conformal radiotherapy. Radiotherapy and Oncology, 2019, 133, S865-S866.	0.6	0
77	Hypofractionated breast irradiation: a multidisciplinary review of the Senonetwork study group. Medical Oncology, 2021, 38, 67.	2.5	O
78	Response Assessment and Follow-Up by Imaging in Breast Tumors. Medical Radiology, 2020, , 451-474.	0.1	0